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Abstract
Background: Glioblastomas are characterized by rapid cell growth, aggressive CNS infiltration, and are resistant to all 
known anticancer regimens. Recent studies indicate that fibrates and statins possess anticancer potential. Fenofibrate 
is a potent agonist of peroxisome proliferator activated receptor alpha (PPARα) that can switch energy metabolism 
from glycolysis to fatty acid β-oxidation, and has low systemic toxicity. Fenofibrate also attenuates IGF-I-mediated 
cellular responses, which could be relevant in the process of glioblastoma cell dispersal.
Methods: The effects of fenofibrate on Glioma cell motility, IGF-I receptor (IGF-IR) signaling, PPARα activity, reactive 
oxygen species (ROS) metabolism, mitochondrial potential, and ATP production were analyzed in human glioma cell 
lines.
Results: Fenofibrate treatment attenuated IGF-I signaling responses and repressed cell motility of LN-229 and T98G 
Glioma cell lines. In the absence of fenofibrate, specific inhibition of the IGF-IR had only modest effects on Glioma cell 
motility. Further experiments revealed that PPARα-dependent accumulation of ROS is a strong contributing factor in 
Glioma cell lines responses to fenofibrate. The ROS scavenger, N-acetyl-cysteine (NAC), restored cell motility, improved 
mitochondrial potential, and increased ATP levels in fenofibrate treated Glioma cell lines.
Conclusions: Our results indicate that although fenofibrate-mediated inhibition of the IGF-IR may not be sufficient in 
counteracting Glioma cell dispersal, PPARα-dependent metabolic switch and the resulting ROS accumulation strongly 
contribute to the inhibition of these devastating brain tumor cells.
Background
Glial neoplasms account for nearly 50% of adult primary
brain tumors, and Glioblastoma multiforme (GBM) is
considered one of the most malignant type of CNS
tumors [1,2]. GBMs originate from glial cells in the brain
and/or spinal cord, and are characterized by rapid cell
growth, resistance to radio- and chemo-therapies, and
relentless spread of neoplastic cells within the CNS [1].
Currently, the treatments that prolong to some extent the
survival of GBM patients are invasive surgery, and
aggressive radiotherapy, followed by chemotherapy
(temolozomid [3,4]); treatment with antibodies and
inhibitors (imatinib, getifinib, avastin [5]), or anti-growth
factor therapy (for instance antisense strategies against
IGF-I or TGFβ [6,7]), which increase survival up to 18-24
months, instead of 8-11 months of classic survival if only
surgery and radiotherapy are applied.
GBMs are characterized by a wide variety of genomic
abnormalities including loss of heterozygosity for 10q,
EGFR amplification and/or mutations, p16 deletions, as
well as p53 and PTEN mutations [8,9]. In addition, the
IGF-I receptor (IGF-IR) signaling system has been sus-
pected for a quite some time as a contributing factor in
supporting malignant growth and invasion of Glioma
cells [6,10,11]. It has also been reported that inhibition of
the IGF-IR expression, either by antisense or triple helix
strategies, triggered apoptotic death in Glioma cells in
vitro, especially under conditions of anchorage-indepen-
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dence, and attenuated tumor growth in experimental ani-
mals [6,10,11].
Previously, we have demonstrated that activation of
Peroxisome Proliferator Activated Receptor alpha (PPAR-
α) by fenofibrate, attenuated signaling responses of the
IGF-IR [12]. In addition, fenofibrate inhibited growth and
compromised survival of several Medulloblastoma [12]
and Melanoma [13,14] cell lines. In other studies, the
anticancer effects of fenofibrate have been demonstrated
in colon, breast, endometrial and skin cancer cell lines
[15-19]. Fenofibrate is a specific agonist of PPARα, which
belongs to the family of steroid hormone nuclear recep-
tors [20], and is characterized by relatively low systemic
toxicity [13,14]. PPAR ligands have been almost exclu-
sively associated with the treatment of diabetes, hyperlip-
idemia and cardiovascular diseases, as they modulate the
expression of genes regulating glucose and lipid metabo-
lism [21]. For instance fenofibrate has been widely used to
lower plasma levels of triglycerides and cholesterol, to
improve LDL : HDL ratio, and to prevent atherosclerosis
[22]. Although, we still do not fully understand how anti-
atherosclerotic effects of fenofibrate could be related to
its action against Glioma cell motility, its wide spectrum
of lipid modifying actions, including strong activation of
fatty acid β-oxidation, inhibition of glycolysis [16,23] and
ROS accumulation [24,25], as well as inhibition of the
IGF-IR signal transduction [12], all require further exam-
ination.
Since the effects of fenofibrate have not been studied in
Gliomas, and fenofibrate attenuates IGF-IR signaling
pathways, we asked first if fenofibrate action against the
IGF-IR could repress malignant dissemination of these
brain tumor cells. Our present in vitro studies were ini-
tially planed to target the IGF-IR signaling pathways, and
are not directly related to other aspects of the IGF system,
which on the other hand may relate to the immune mech-
anism of tumor pathology [6,26]. Here we demonstrate
that IGF-I-induced and serum-induced motility of
Glioma cell lines were both severely attenuated by fenofi-
brate, which depended, at least partially, on the activation
of PPARα. Surprisingly, specific attenuation of the IGF-IR
function by low molecular weight IGF-IR tyrosine kinase
inhibitor, NVP-AEW541, had only modest effects on
Glioma cell motility in serum stimulated LN-229 cells,
and had practically no effect on T98G cells. Further anal-
yses pointed to the accumulation of the reactive oxygen
species (ROS) as an additional mechanism of the fenofi-
brate action since the ROS scavenger, N-acetyl-cysteine
(NAC), effectively restored Glioma cell motility. Our
results show that in addition to the attenuation of the
IGF-IR, fenofibrate action involves accumulation of ROS,
loss of mitochondrial membrane potential, and a deficit
in ATP production, which taken together may explain the
severe impairment of Glioma cell motility. Further stud-
ies are necessary to determine if indeed treatment with
fenofibrate could be effective against Glioma cell disper-
sal in the CNS.
Methods
Cell Culture
The human Glioma cell lines used in this study include:
U-87MG (ATCC# HTB14), U-118MG (ATCC# HTB-15),
T98G (ATCC# CRL-1690), LN-18 (ATCC# CRL-2610)
and LN-229 (ATCC# CRL-2611). In addition, R600
mouse embryo fibroblasts, which express 30,000 of the
human IGF-IR per  cell [27], and primary cultures of
human fetal astrocytes (Cambrex) were included as con-
trols. Human fetal astrocytes were cultured according to
the manufacturer recommendations (Cambrex). The
Glioma cell lines were maintained as monolayer cultures
in DMEM supplemented with 50 U/ml penicillin, 50 ng/
ml streptomycin, and 10% fetal bovine serum (FBS) at
37°C in a 7% CO2 atmosphere. The cells were made par-
tially quiescent by 48 hours incubation in serum-free
medium (SFM) (DMEM supplemented with 0.1% bovine
serum albumin). Cell motility and cell signaling were
tested by stimulating serum-starved cells with 50 ng/ml
of recombinant IGF-I in the presence or absence of 50
μ M  f e n o f i b r a t e .  I n  s o m e  e x p e r i m e n t s ,  e x p r e s s i o n  o f
PPARα was inhibited by utilizing ON-TARGETplus
SMARTpool siRNA against human PPARα: CCCGUUA
UCUGAAGAGUUC; GCUUUGGCUUUACGGAAUA;
GACUCAAGCUGGUGUAUGA; GGGAAACAUCCA-
AGAGAUU (Thermo Scientific).
Western Blot Analysis
To evaluate phosphorylation levels of the selected IGF-IR
signaling molecules, semi quiescent cultures were stimu-
lated with IGF-I and total protein extracts collected. The
following primary anti-phosphospecific antibodies were
utilized: anti-pY612IRS-1 rabbit polyclonal (BioSource,
Camarillo, CA); anti-pS473Akt, anti-pT202/Y204Erk1/2,
and anti-pS21/9GSK3α/β (Cell Signaling Technology, Inc.
Danvers, MA) In addition, anti-PPARα mouse monoclo-
nal antibody (Chemicon) was utilized. To monitor load-
ing conditions anti-IRS-1 (Upstate USA Inc.,
Charlottesville, VA), anti-GSK3β, anti-Akt, anti-Erks
(Cell Signaling, Danvers, MA) and anti-Grb-2 antibodies
were used.
Cell Motility Assays
Images of migrating cells were recorded and analyzed by
computer-aided methods, as previously described
[28,29]. Cells were cultured in Corning flasks until they
reached confluency. A cell-free area was introduced by
scraping the monolayer with pipette tip. Cell migration
into cell-free area was evaluated for 10 hours in the pres-
ence of 10% FBS (positive control); in serum-free mediumDrukala et al. Molecular Cancer 2010, 9:159
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(SFM, negative control), following IGF-I stimulation (50
ng/ml); and in the presence or absence of fenofibrate at a
concentration of 50 μM. In some experiments the cells
were pretreated with N-acetylcysteine (NAC). Tracks of
individual cells were generated by determining cell dis-
placements from time-lapse images taken at 20 minutes
intervals during a total observation period of 10 hours.
The position of the "cell centroid" was marked by an
observer on a digitized image as previously described
[28,30]. Fifty cell tracks were recorded under each of the
experimental conditions tested. The cell trajectories were
presented in circular diagrams with the starting point of
each trajectory located in the diagram center. The follow-
ing parameters characterizing cell locomotion were com-
puted for each cell using Mathematical Procedures
including: total length of cell trajectory (μm); average
speed of cell locomotion (μm/min); length of final cell
displacement (μm) i.e. the distance between, first and last
point of the cell track; and a ratio of cell displacement
length to cell trajectory length - coefficient of dislocation
efficiency (CDE). In addition, cell migration was assessed
in Transwell™ Chambers (Corning Corporation, USA)
with polycarbonate filters (6.5 mm in diameter; 8.0 μm
pore size). The cells were suspended in 200 μl of culture
medium and were treated as indicated in the results sec-
tion. After 48 hrs the inserts were washed with PBS, the
non-migratory cells were wiped out with cotton swabs
(upper site of the filter), and the filters were fixed and
stained with crystal violet : carbol : 25% methanol (1:1:2)
mixture for 20 min. The remaining blue-stained cells,
which migrated across the membrane were counted
under bright light inverted microscopy.
Luciferase Assay
The transcriptional activity of PPARs in LN-229 human
Glioma cell line was determined by utilizing a JsTkpGL3
reporter plasmid, which contains luciferase gene driven
by PPAR responsive element (PPRE), which consists of
three copies of the J site from apo-AII gene promoter
[31]. The activation of PPAR elements was evaluated by
dual-Firefly/Renilla luciferase reporter system (Promega,
Madison, WI), using Femtomaster FB12 chemiluminom-
eter (Zylex. Corp).
Intracellular ROS accumulation
Viable cells were loaded with 1 mM oxidant sensitive dye
Redox Sensor Red CC-1, and with 50 nM of mitochon-
drial specific dye MitoTracker Green FM as previously
described [32]. The images were taken with an inverted
Nikon Eclipse TE300 microscope equipped with a Retiga
1300 camera, motorized Z-axis, Nikon Plan Fluor 40×/
1.3 Oil objective, and deconvolution software
(SlideBook4). The quantification of intracellular ROS and
ROS co-localization with mitochondria was calculated
from the entire volume of the cell by utilizing the Mask
Operation included in SlideBook4 software, according to
manufacturer instructions (Intelligent Imaging Innova-
tions, Denver CO).
Mitochondrial Potential
This measurement was performed by flow cytometry
based MitoPotential Kit according to the manufacturer
protocol (Guava Easy Cyte). Loss of the mitochondrial
inner transmembrane potential (ΔΨm) was evaluated by
utilizing the cationic dye JC-1, which gives either green or
orange fluorescence depending upon mitochondrial
membrane depolarization [33]. The cells were treated
either with vehicle (DMSO) or 50 μM fenofibrate. Follow-
ing 24 hrs incubation, the cells were harvested by
trypsinization, loaded with JC-1 for 30 min and immedi-
ately analyzed by Guava EastCyte flowcytometer using
Mito-Potential software (Guava Technologies, Inc).
ATP production
Modified methodology described by Gato et al. was fol-
lowed [34]. ATP levels were measured by ApoSENSOR
ADP/ATP Ratio Assay Kit according to the manufacturer
recommendations (BioVision). The cells were treated
either with vehicle (DMSO) or 50 μM fenofibrate. After
48 hrs, the cells were harvested by trypsinization and 1 ×
104 cell aliquots were resuspended in 100 μl of Nucleotide
Releasing Buffer, 1 μl of ATP Monitoring Enzyme and 1 μl
of ADP Converting Enzyme. The luminometric measure-
ment was performed using EnVision multi-plate reader
(PerkinElmer).
Results
Detection of IGF-IR, IRS-1 and PPARα in Glioma cell lines
In view of recent findings, which demonstrated the inhib-
itory action of fenofibrate against IGF-IR signaling [12],
we evaluated IGF-IR, its major signaling molecule, Insu-
lin Receptor Substrate 1 (IRS-1), and PPARα protein lev-
els in five human Glioma cell lines in comparison to
primary cultures of human fetal astrocytes. Western blot
depicted in Fig. 1A demonstrates that LN-18 and LN-229
Glioma cell lines are characterized by elevated protein
levels for IGF-IR and IRS-1 in comparison to control fetal
astrocytes. In contrast, IGF-IR levels in U87MG, U-
118MG and T98G are very low. Interestingly, T98G cells
despite of very low IGF-IR expression retained elevated
IRS-1. All five human Glioma cell lines demonstrated ele-
vated PPARα protein levels in comparison to human fetal
astrocytes (Fig. 1B). Importantly, exponentially growing
LN-229 cells (in 10% FBS), showed both cytosolic and
nuclear PPARα subcellular localization which shifted
towards the nuclear compartment following 24 hrs cell
incubation with fenofibrate (Fig. 1C). Quantitatively, an
average of 7.6% and 2.8% of the nuclear content (DAPIDrukala et al. Molecular Cancer 2010, 9:159
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Figure 1 Characterization of IGF-IR, IRS-1 and PPAR-α in human Glioma cell lines. Western blot analysis showing IGF-IR, IRS-1 (Panel A), and 
PPAR-α protein levels (Panel B) in exponentially growing five human Glioma cell lines in comparison to primary human fetal astrocytes, and R600 
mouse embryo fibroblasts, which express 30,000 IGF-IR molecules/cell and high levels of IRS-1. Note that U87MG and U-118MG, which do not express 
PTEN [8], demonstrate very low levels of the IGF-IR and its major signaling molecule, IRS-1. In T98G, in which activity of PTEN is compromised by point 
mutation [8], IGF-IR is also very low; however IRS-1 is not affected. Equivalent loading was demonstrated by re-probing membranes with anti-Grb-2 
antibody. Panel C: Quantification of PPARα nuclear localization (co-localization with DAPI) in exponentially growing LN-229 cells in the presence (FBS 
+ FF) and absence (FBS) of fenofibrate treatment. The nuclear co-localization was calculated from the entire volume of the nucleus by utilizing Mask 
Operation included in SlideBook4 software, according to manufacturer instructions (Intelligent Imaging Innovations, Denver Co.). The data represent 
average number of voxels per nucleus +/- SD, (n = 25). * indicates values significantly different from FBS (p≤0.05). Images below the histogram repre-
sent examples of PPARα subcellular distribution. Panel D: PPARα transcriptional activity was evaluated in LN-229 cells by utilizing a dual-Firefly/Renilla 
luciferase reporter system and Femtomaster FB12 chemiluminometer. Data are presented as mean ± SD calculated from two experiments in triplicates 
(n = 6). * indicates value statistically significantly different (p≤0.05) from control (FBS; cells treated with vehicle only). Statistical significance between 
two measurements was determined with the two-tailed Student's t-test.Drukala et al. Molecular Cancer 2010, 9:159
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labeled) co-localized with PPARα in the presence and
absence of the fenofibrate treatment, respectively (n =
25). This 2.7-fold increase in nuclear PPARα was accom-
panied by almost 4-fold increase in PPAR-transcriptional
activity (Fig. 1D), further supporting the possibility of
using fenofibrate to trigger PPARα-mediated responses in
Glioma cells.
Fenofibrate-mediated attenuation of the IGF-IR signaling 
responses
Results in Fig. 2A demonstrated a strong downregulation
of the phosphorylation of IRS-1, Akt, ERKs, and GSK-3β
in LN-229 cultured in serum-free medium (SFM). Fol-
lowing IGF-I stimulation, all four signaling molecules
became highly phosphorylated. We have previously
reported that fenofibrate inhibited IGF-I-induced phos-
phorylation events in Medulloblastoma cell lines [12].
Considering that LN-229 Glioma cells responded to IGF-
I stimulation, we have examined the effects of fenofibrate
on IGF-I-induced phosphorylation events. As shown in
Fig. 2A, pre-incubation of LN-229 cells with 50 μM feno-
fibrate (IGF + FF) attenuated IGF-I-induced phosphory-
lation of IRS-1, ERKs, Akt and GSK-3β.
Since IGF-I can also stimulate cell motility [35], we
evaluated effects of IGF-I on LN-229 cell motility by uti-
lizing cell displacement (Figs. 2Band 2C, upper panels)
and wound healing assays (Figs. 2B and 2C, lower panels).
The results demonstrate that following scratch induced
monolayer injury LN-229 migrated into the cell-free
areas with different efficiency (lower panels). The cells
cultured in SFM covered only 6.1 +/-2% of the free sur-
face, and the cells stimulated with IGF-I covered 57.1 +/-
5% of the scratched area over the period of 10 hours. Fol-
lowing 24 hrs of cell pre-incubation with 50 μM fenofi-
brate, IGF-I-induced cell motility was reduced over 2-fold
(from 57.1 +/-5% to 27 +/-6%). Since the percentage of
cells covering the scratched area may result also from cell
proliferation, to clarify the contribution of cell motility in
this process, we have included the cell displacement
assay. Fig. 2B (upper panel) demonstrates trajectories of
50 migrating LN-229 cells in SFM, and following IGF-I
stimulation in the presence or absence of fenofibrate. The
circular diagrams were drawn in the initial point of each
trajectory placed at the origin of the plot as previously
described [28,29]. The determination of cell trajectories
is necessary to discriminate between overall cell motility/
proliferation (wound healing) and the final effective cell
displacement [30]. The final cell displacement of LN-229
migrating in the presence of IGF-I was more than 3-fold
greater than in SFM, and the total length of trajectories in
cells stimulated by IGF-I increased 1.5-fold in compari-
son to SFM (Fig.2B and Table 1). In the presence of feno-
fibrate, final cell displacement was reduced by 1.8-fold
and the total length of trajectories decreased by 1.4-fold.
This inhibition was associated also with significant
decreases in average speed (from 0.18 μm/min to 0.13
μm/min) and CEM (from 0.48 to 0.39) (Tables 1 and 2),
further confirming the attenuation of Glioma cell motility
by fenofibrate.
Contribution of IGF-IR inhibition to fenofibrate-mediated 
action against serum-induced Glioma cell motility
Since fenofibrate inhibited IGF-I-induced phosphoryla-
tion events and repressed IGF-I-induced LN-229 cell
motility, we asked whether direct inhibition of the IGF-IR
by the specific small molecular weight IGF-IR inhibitor,
NVP-AEW541, could have a similar inhibitory action.
The results in Fig. 2C show that both IGF-I responsive,
LN-229, and non-responsive T98G Gliona cell lines were
characterized by very active cell migration when cultured
in the presence of serum (10% FBS). In particular, 78.5 +/
-9% and 94.5 +/-4% of the scratched area were repopu-
lated by LN-229 and T98G cells, respectively. In serum
stimulated LN-229, fenofibrate treatment decreased cell
expansion into the scratched areas by 15-fold (from 78.5%
to 5.1%) and in T98G by 11-fold (from 94.7% to 8.6%).
Surprisingly, the IGF-IR inhibitor, NVP-AEW541, was
much less effective showing only a modest reduction in
cell motility: 1.5-fold decrease in LN-229 cells, and 1.1-
fold decrease in T98G cells (Fig. 2C lower panel). Corre-
sponding trajectories for both cell lines are illustrated as
circular diagrams in Fig. 2C (upper panel). Analyses of
individual cell trajectories showed that 10% FBS strongly
stimulated cell motility of LN-229 and T98G. The average
speed of movement (i.e. total length of cell trajectory/
time), the cell displacement, and the coefficient of move-
ment efficiency (CME) are presented in Tables 1 and 2.
These results demonstrate that the observed inhibition in
the motile activity of the cells resulted from both
decrease in speed and polarization of movement. Inhibi-
tion of the IGF-IR by 1 μM NVP-AEW541, which has
been shown in our previous work to repress IGF-IR
tyrosine kinase activity in Medulloblastoma [36], only
partially attenuated serum-induced LN-229 cell motility
and had practically no effect on T98G cells (Fig. 2C;
Tables 1 and 2). However, LN-229 cells showed a 1.5-fold
decrease in the average cell displacement after NVP-
AEW541 treatment, indicating a partial contribution of
the IGF-IR in this IGF-I responsive Glioma cell line.
Effects of ROS scavenger NAC on fenofibrate-induced 
inhibition of cell motility, mitochondrial potential and ATP 
production
Since attenuation of the IGF-IR signalling responses con-
tributed only minimally to the fenofibrate-induced inhi-
bition of Glioma cell lines, we asked whether the
metabolic action of fenofibrate [16] could explain its anti-
invasive potential. This could be relevant, since fenofi-Drukala et al. Molecular Cancer 2010, 9:159
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Figure 2 Fenofibrate inhibits IGF-induced LN-229 cellular responses. Panels A: Western blot analyses showing phosphorylated (active) forms of 
IRS-1 (pY612), Akt (pS473), ERKs (pT202/pY204) and GSK-3β (pS21/9) in LN-229 human Glioma cells following 48 hrs serum starvation (SFM); IGF-I stim-
ulation (50 ng/ml) for 30 min (IGF), and when IGF-I stimulation was preceded by 24 hrs cell pre-incubation with 50 μM fenofibrate (IGF + FF). Antibodies 
against non-phosphorylated forms of IRS-1, Akt, ERKs, as well as anti-Grb-2 antibody, were used to demonstrate equal protein loading. Panel B: Upper 
image: Trajectories of 50 migrating LN-229 cells in SFM, and following IGF-I stimulation in the absence (SFM + IGF) and in the presence (SFM + IGF + 
FF) of 50 μM fenofibrate. Data are displayed in circular diagrams drawn in the initial point of each trajectory placed at the origin of the plot. The posi-
tions of the "cell centroid" from the consecutive frames were used for generation of cell tracks. Quantification of multiple cell motility parameters is 
given in Table 1. Lower image: Live cell time-lapse imaging of LN-229 cells at 10 hrs after scratching the monolayer culture with the pipette tip. The 
numbers below phase-contrast images indicate % decrease of the scratched areas (+/- SD, n = 3), calculated from the cell-free area measured at time 
zero and following 10 hrs of continuous cell migration. Panel C: Upper image: Trajectories of 50 migrating LN-229 and T98G cells the presence of 10% 
FBS (FBS); 10% FBS + 50 μM fenofibrate (FBS + FF); and 10%FBS + 1 μM IGF-IR inhibitor, NVP-AEW541, (FBS + NVP). Quantification of the cell migration 
parameters are presented in Table 1. Lower image: Cell migration into the scratched cell-free areas were evaluated at time zero (T0, just after the 
scratch) and after 10 hrs of continuous cell migration into the cell-free area in the presence of 10%FBS (FBS); 10% FBS + 50 μM fenofibrate (FBS + FF); 
and 10%FBS + 1 μM IGF-IR inhibitor NVP- AEW541 (NVP). The numbers below phase-contrast images of the scratched monolayer indicate average 
percentage of the scratched area re-occupied by the migrating cells for 10 hrs (+/-SD, n = 3).Drukala et al. Molecular Cancer 2010, 9:159
http://www.molecular-cancer.com/content/9/1/159
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brate via activation of PPARα is expected to force mito-
chondrial fatty acid β-oxidation in tumor cells, which are
often characterized by mitochondrial dysfunction, and
strongly rely on glycolysis as the main energy pathway
[16,37,38]. Since dysfunctional mitochondrial respiration
and oxidative phosphorylation contribute to ROS accu-
mulation [39,40], which may further compromise ATP
production and repress cell motility, we have evaluated
effects of fenofibrate on ROS accumulation. As shown in
Fig. 3A, incubation of LN-229 cells with 50 μM fenofi-
brate for 24 hours (FF) resulted in a significant accumula-
tion of intracellular ROS, demonstrated here by orange/
red fluorescence in cells loaded with the redox sensitive
fluorescent dye, CC-1 red, and with the mitochondrial
marker, mito-tracker green [41]. Importantly, when ROS
scavenger, N-acetyl-cystein (NAC), accompanied the
fenofibrate treatment the accumulation of ROS was effec-
tively reduced. The intensity of total ROS - associated flu-
Table 1: Analyses of Glioma Individual Cell Displacement
Conditions\Parameters Total length of cell 
trajectory (μm)
Average speed of cell 
movement (μm/min)a
Length of final cell 
displacement (μm)
Average rate of cell 
displacement (μm/min) b
Coefficient of 
movement 
efficiency (CME) c
SFM 76.58 ± 2.05* 0.13 ± 0.003* 17.58 ± 1.50* 0.03 ± 0.002* 0.23 ± 0.02*
SFM + IGF 112.8 ± 3.6** 0.18 ± 0.005** 55.89 ± 3.87** 0.09 ± 0.005** 0.48 ± 0.02**
SFM + IGF + FF 80.5 ± 1.64 0.13 ± 0.002 31.07 ± 1.79** 0.05 ± 0.002** 0.39 ± 0.02**
FBS 105.04 ± 2.9 0.175 ± 0.005 67.30 ± 3.07 0.11 ± 0.005 0.64 ± 0.02
FBS + FF 59.61 ± 1.82* 0.01 ± 0.003* 16.83 ± 1.52* 0.02 ± 0.003* 0.27 ± 0.02*
FBS + NVP 94.47 ± 2.35 0.16 ± 0.005 45.27 ± 2.70* 0.07 ± 0.004* 0.47 ± 0.04*
FBS + FF + NAC 105.51 ± 2.6 0.17 ± 0.005 59.03 ± 2.50 0.09 ± 0.004 0.56 ± 0.02
Individual tracks of LN-229 cell locomotion were generated by determination of cell centroid displacements with time-lapse images taken at 20 
minutes intervals during a total observation period of 10 hours. The positions of the cell centroid were marked by an observer on a digitized 
image. Fifty cell tracks were recorded under each of the experimental conditions tested. The cell trajectories were presented in circular diagrams 
with the starting point of each trajectory situated in the diagram centre. a: the average speed of cell locomotion is defined as the total length of 
cell trajectory/time of recording (10 hrs). b: the average rate of cell displacement is defined as the total length of cell displacement from the 
starting point to the final cell position/time of recording (10 hrs). c: the ratio of cell displacement to cell trajectory length. CME would equal 1 for 
the cell moving persistently along one straight line in one direction and 0 for a random movement [68]. The values are given as the mean +/-SEM 
(n = 50). * Statistically different from FBS at p≤0.05. ** Statistically different from SFM at p≤0.05.
Table 2: Analyses of Glioma Individual Cell Displacement.
Conditions\Parameters Total length of cell 
trajectory (μm)
Average speed of cell 
movement (μm/min)a
Length of final cell 
displacement (μm)
Average rate of cell 
displacement (μm/min) b
Coefficient of 
movement 
efficiency (CME) c
FBS 206.3 ± 4.6 0.34 ± 0.07 192.99 ± 5.30 0.32 ± 0.008 0.83 ± 0.04
FBS + FF 83.30 ± 2.6* 0.14 ± 0.05* 58.12 ± 2.10* 0.09 ± 0.003* 0.45 ± 0.02*
FBS + NVP 217.03 ± 6 0.36 ± 0.009 201.31 ± 6.61 0.33 ± 0.01 0.8 ± 0.01
FBS + FF + NAC 132.4 ± 3.4 0.22 ± 0.005 67.7 ± 2.8 0.11 ± 0.005 0.51 ± 0.02
Individual tracks of T98G cell locomotion were generated by determination of cell centroid displacements with time-lapse images taken at 20 
minutes intervals during a total observation period of 10 hours. All experimental parameters are identical to those described in the legend to 
Table 1. The values are given as the mean +/-SEM (n = 50). * Statistically different from FBS at p≤0.05. ** Statistically different from SFM at p≤0.05.Drukala et al. Molecular Cancer 2010, 9:159
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Figure 3 Effects of fenofibrate on intracellular ROS accumulation . Panel A: Exponentially growing LN229 and T98G cells (in 10%FBS) were treat-
ed with 50 μM fenofibrate (FF), in the presence or absence of ROS scavenger, N-acetyl-cysteine (NAC). The cells were loaded with Redox Sensor Red 
CC-1, and MitoTracker Green FM as previously described [41]. A series of three-dimensional images of each individual picture were deconvoluted to 
one two-dimensional picture and resolved by adjusting the signal cut-off to near maximal intensity to increase resolution. Note strong increase in 
cytosolic (red fluorescence) and mitochondria associated (yellow fluorescence) ROS accumulation following fenofibrate treatment (FF), which was 
effectively prevented by NAC (FF + NAC). Panel B: The quantification of intracellular ROS (voxels per cell) in LN-229 and T98G glioma cell lines, respec-
tively. The results were collected from the entire volume of the cell and calculated by utilizing Mask Operation included in SlideBook4 software, ac-
cording to manufacturer instructions (Intelligent Imaging Innovations, Denver Co.). The data represent average number of voxels per cell +/- SD, (n = 
3). * indicates value significantly different from FBS; ** indicates value significantly different from FF (p ≤ 0.05). Panel C: Cell motility evaluated by cell 
displacement (upper image) and scratch assay (lower image). Upper image: Trajectories of 50 migrating LN-229 and T98G cells in 10%FBS supplemented 
with 50 μM fenofibrate in the absence (FBS + FF) and in the presence of NAC (FBS + FF + NAC). Quantification of multiple cell motility parameters is 
given in Table 1. Lower image: Live cell time-lapse imaging of LN-229 and T98G cells at 10 hrs after scratching the monolayer culture with the pipette 
tip. The numbers below phase-contrast images indicate % decrease of the scratched areas (+/- SD, n = 3), calculated from the cell-free area measured 
at time zero and following 10 hrs of continuous cell migration.Drukala et al. Molecular Cancer 2010, 9:159
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orescence increased 3.2-fold in LN-229 cells (Fig. 3B) and
3.7-fold in T98G cells (Fig. 3C) following the treatment
with fenofibrate (FF). In the presence of NAC (FF +
NAC), both IGF-I responsive LN-229, and non-respon-
sive T98G cells did not accumulate ROS following fenofi-
brate treatment, showing the values for ROS associated
fluorescence even lower than those detected in control
cultures (FBS). These results suggest that fenofibrate-
mediated accumulation of ROS happens independently
from the IGF-IR, and that ROS scavenger NAC signifi-
cantly counteracted fenofibrate-mediated ROS accumu-
lation in both LN-229 and in T98G Glioma cells.
Next, we asked if ROS inhibition by NAC could rescue
Glioma cell motility. The results in Fig. 3C and in Tables 1
and 2 show that fenofibrate-induced inhibition of LN-229
and T98G cell motility was effectively counteracted by 10
mM NAC. We have further confirmed NAC-mediated
effects against fenofibrate by analyzing LN-229 cell inva-
siveness in the Transwell™ Chambers. The results
depicted in Fig. 4D show that in 10% FBS, LN-229 cells
migrated across the 8 μm pores very effectively. This
invasive propensity was significantly counteracted by the
fenofibrate treatment, and was partially neutralized by
NAC. Importantly, simultaneous treatment of LN-229
and T98G cells with fenofibrate and NAC resulted in par-
tial restoration of mitochondrial potential (Fig. 4A and
4B), and improved ATP production in fenofibrate treated
cells, confirming the involvement of ROS in fenofibrate
inhibitory action/s against Glioma cell lines (Fig. 4C).
Effects of PPARα inhibition on fenofibrate action against 
Glioma cell motility
To verify whether fenofibrate-mediated ROS accumula-
tion and inhibition of Glioma cell motility depends on
PPARα, we have utilized PPARα siRNA. Results in Fig. 5A
show that 48 hrs cell preincubation with 100 and 200 μM
SmartPool siRNA designed to target specifically PPARα
mRNA, resulted in almost 5-fold and over 20-fold
decrease PPARα protein levels, respectively. Importantly,
this strong PPARα inhibition counteracted fenofibrate-
induced accumulation of ROS (Fig. 5B), and effectively
rescued LN-229 cell motility in the presence of fenofi-
brate. In summary, our results show a strong inhibitory
action of fenofibrate against Glioma cell motility. This
i n h i b i t o r y  a c t i o n  r e l i e s  o n  R O S  a c c u m u l a t i o n  a n d  i s
mediated at least partially by the activation of PPARα. In
contrast, downregulation of the IGF-IR induced by feno-
fibrate has only a modest contribution to the inhibition of
Glioma cell motility despite the fact that IGF-I stimulates
invasiveness of IGF-I-responsive LN-229 cells.
Discusion
Our presented work is an in vitro study in which we eval-
uate the involvement of IGF-IR and ROS in fenofibrate/
PPARα -mediated inhibition of Glioma cell motility. Our
experimental setting is based on human glioma cell
model obtained from ATCC, and although our results
cannot be directly extrapolated the existing mechanisms
that control Glioblastoma invasiveness in vivo, we have
shown their potential usefulness for future clinical
research studies.
Here, we have evaluated cellular and molecular
responses of Glioma cells to fenofibrate, and we attempt
to discuss its potential use as a new therapeutic agent
against Glioblastoma. In this respect our preliminary
studies (not shown) demonstrate elevated levels of
PPARα in multiple Glioblastoma clinical samples. Inter-
estingly, PPARα was detected preferentially in the cyto-
plasm of the tumor cells, and nuclear PPARα was found
only in restricted areas of the tumor adjacent to the
necrotic tumor tissue. This prominent presence of cyto-
solic PPARα, which belongs to the family of nuclear ste-
roid receptors, may indicate that its transcriptional
activity in Glioblastomas is low in comparison to the
nuclear PPARα detected in the control normal brain tis-
sues in which both neurons and astrocytes were positive
(preliminary observations). This may also suggest that
Glioblastoma cells require exogenous stimulation to acti-
vate/translocate PPARα to the nucleus. Indeed, the
results in Fig. 1D confirmed enhanced PPARα transcrip-
tional activity following fenofibrate treatment, which was
accompanied by increased detection of PPARα in the
nuclei of LN-229 Glioma cells (Fig. 1C).
Since in our previous studies fenofibrate attenuated
IGF-IR in Medulloblastoma cell lines [12], we are asking
here if fenofibrate could compromise this signaling path-
way in human Glioma cell lines. We have selected LN-229
and T98G human Glioma cell lines, which express high
and low levels of the IGF-IR, respectively (Fig. 1A). In
contrast to T98G, LN-229 cells responded to IGF-I stim-
ulation by elevated cell proliferation (data not shown),
and increased cell motility (Fig. 2B). Since, these
responses of LN-229 cells were effectively blocked by
fenofibrate, we suspected first that fenofibrate-mediated
attenuation of the IGF-IR signaling is responsible for its
inhibitory action. Interestingly, fenofibrate also inhibited
serum-induced cell motility not only in IGF-I sensitive
LN-229 cells, but also in T98G cells, which do not
respond well to IGF-I stimulation. Surprisingly, serum-
stimulated LN-229 and T98G cells were both resistant to
small molecular weight IGF-IR inhibitor, NVP-AEW541,
which effectively inhibited growth and survival of several
other tumor cell lines including Medulloblastoma, colon
and prostate cancer [36,42,43]. These minimal effects of
IGF-IR inhibition on Glioma cell motility could explain
only moderate clinical results obtained in the treatment
of malignant astrocytomas using antisense strategies [44].
Antisense strategies in which immune response ratherDrukala et al. Molecular Cancer 2010, 9:159
http://www.molecular-cancer.com/content/9/1/159
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Figure 4 Effects of fenofibrate and NAC on mitochondrial function. Panels A and B: Mitochondrial potential was evaluated in LN-229 and T98G 
cells, respectively, by utilizing flowcytometry based MitoPotential Kit according to manufacturer's protocol (Guava EasyCyte). Loss of mitochondrial 
inner transmembrane potential (ΔΨm) was evaluated by a cationic dye JC-1 that gives either green or orange fluorescence depending upon mito-
chondrial membrane depolarization. The cells growing in 10% FBS were treated either with vehicle (DMSO) or with 50 μM fenofibrate in the absence 
(FBS + FF50) or in the presence of NAC (FBS + FF50 + NAC). Following 24 hrs incubation, the cells were loaded with JC-1 for 30 minutes and analyzed 
by Guava EastCyte flowcytometer using Mito-Potential software. Note that fenofibrate treatment increases percentage of cells with compromised mi-
tochondrial potential. Quantification of the mitochondrial potential is shown in the last panel. Data represent average percentage of cells showing 
polarized or depolarized mitochondria +/- SD, (n = 3). Panel C: ATP levels were evaluated by ApoSENSOR ADP/ATP Ratio Assay Kit (BioVision). The 
luminometric measurement was performed using EnVision multi-plate reader (PerkinElmer). Data are presented as mean ± SD calculated from two 
experiments in triplicates (n = 6). * indicates values statistically different from FBS. ** indicates values statistically different from FF, (p ≤ 0.05). Note a 
strong inhibition of ATP production following 48 hrs cell exposure to 50 μM fenofibrate (FF), which was effectively prevented by the ROS scavenger, 
NAC. Panels D: Effects of IGF-I, fenofibrate and NAC on LN-229 cell migration evaluated in Transwell Chambers. The cells were seeded at the density 
of 5 × 104/chamber in 200 μl of 10%FBS containing culture medium (control). The cells were additionally treated with 50 μM fenofibrate either in the 
absence (FF) or in the presence of NAC (FF + NAC). In addition, we have evaluated cell migration in serum-free medium (SFM) and in SFM supple-
mented with IGF-I (50 ng/ml). Data are presented as mean ± SD from three independent experiments in duplicates (n = 6). Statistical significance was 
tested between control and FF (*), between FF and FF + NAC (**), and between SFM and SFM + IGF (***); p≤0.05.Drukala et al. Molecular Cancer 2010, 9:159
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Figure 5 Effects of PPARα siRNA on fenofibrate-mediated ROS accumulation and cell motility. Panel A: Western blot analysis showing PPARα 
protein levels in LN-229 cells incubated with 200 μM of irrelevant siRNA against nuclear lamins (NL: 200 μM), and with 100 and 200 μM of ON-TARGRT 
plus SMARTpool siRNA against human PPARα (Thermo Scientific). The histogram below indicates densitometric analysis of the blot analyzed by 
EZQuant-Gel 2.17 (EZQuant Biology Software Solutions, Tel Aviv, Israel). Panel B: ROS accumulation evaluated in exponentially growing LN229 cells 
(FBS). The cells were treated with 50 μM fenofibrate (FF), in the presence or absence of 200 μM PPARα siRNA (siPPARα). The cells were loaded with 
Redox Sensor Red CC-1, and MitoTracker Green FM as previously described [41]. The quantification of intracellular ROS (voxels per cell) is illustrated 
below. The results were collected from the entire volume of the cell and calculated by utilizing Mask Operation included in SlideBook4 software, ac-
cording to manufacturer instructions (Intelligent Imaging Innovations, Denver Co.). The data represent average number of voxels per cell +/- SD, (n = 
3). * indicates value significantly different from FBS; ** indicates value significantly different from FF (p≤0.05). Panel C: LN-229 cell migration evaluated 
in Transwell Chambers. Experimental conditions are similar to those described in the legend to Fig. 4D. Exponentially growing LN-229 cells (in 10% 
FBS) were treated with 50 μM fenofibrate (FF) in the presence or in the absence of 200 μM siRNA against PPARα. After 48 hrs the cells, which did not 
migrate through the pores, were removed and cells on the bottom surface of the filters were fixed, stained and counted. Data are presented as mean 
± SD from three independent experiments in duplicates (n = 3). Statistical significance was tested between FBS (control) and FF (*), and between FF 
and FF + PPAR siRNA (**); p≤0.05.Drukala et al. Molecular Cancer 2010, 9:159
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than IGF-IR or TGFβ inhibition per se were suggested are
more effective [6,45]. Further, we speculate that although
IGF-I contributes to the malignant spread of LN-229
cells, NVP-AEW541 was not effective since other growth
promoting mechanism/s, in addition to the IGF-IR, could
be involved in supporting dissemination of these tumor
cells. Despite of this resistance to IGF-IR inhibition, feno-
fibrate effectively inhibited Glioma cell motility in the
presence of 10% FBS. Further experiments pointed to the
accumulation of reactive oxygen species (ROS) as a possi-
ble mechanism of the fenofibrate action, since the ROS
scavenger, NAC, effectively restored LN-229 cell motility,
improved mitochondrial potential and enhanced ATP
production in fenofibrate treatment cultures of LN-229
cells.
Another aspect of IGF-IR function is its role in protect-
ing tumor cells from apoptosis [46-48]. Indeed, different
strategies aiming against the IGF-IR were often associ-
ated with apoptotic death of different types of tumor
cells, including Gliomas [6] and Medulloblastomas
[36,49]. Note however, pro-apoptotic effects of IGF-IR
inhibition were observed either when tumor cells were
cultured in the condition of anchorage-independence
[36,50] or when IGF-IR inhibition was used to sensitize
tumor cells to other anticancer treatments [51-53]. In our
experimental setting the treatment of Glioma cells by
fenofibrate, which attenuates IGF-IR signaling was
applied to monolayer cultures, the condition in which
tumor cells are quite resistant to apoptosis. Indeed, we
did not observed any significant increase in Glioma apop-
totic cell death even in the presence of 50 μM fenofinrate,
the concentration, which effectively inhibited both cell
motility and IGF-I -mediated phosphorylations (Fig. 2).
So far, our results indicate that specific inhibition of the
IGF-IR affects only minimally Glioma cell motility (Fig.
2C), which makes them very different from Medulloblas-
toma cell lines in which inhibition of the IGF-IR was suf-
ficient to attenuate their growth and survival in achorage-
independence [12,36]. Although the mechanism by which
fenofibrate attenuates IGF-IR is still under investigation,
our preliminary observations suggest that fenofibrate uti-
lizes a PPARα independent mechanism in repressing this
tyrosine kinase receptor. In this regard, fenofibrate has
been shown to increase plasma membrane rigidity in a
manner similar to elevated cholesterol content in cell
membranes [54]. In this report, fenofibrate did not
change the membrane content of cholesterol, but
increased plasma membrane rigidity, altering activities of
integral membrane proteins such as the endoplasmic
reticulum Ca2+-ATPase and γ-secretase-mediated cleav-
age of APP [54]. Further experiments are required to
determine whether similar fenofibrate-mediated changes
in the fluidity of plasma membrane are indeed responsi-
ble for attenuation of the ligand-induced clustering of the
IGF-IR, a critical step in auto-phosphorylation of the
receptor molecules and the initiation of growth promot-
ing signaling cascades.
Despite of our seemingly contradictory findings, i.e.,
that IGF-I treatment induces Glioma cell motility, how-
ever, the same cells are resistant to the specific IGF-IR
inhibitor; and that fenofibrate attenuates IGF-IR signaling
responses, the fenofibrate treatment was still very effec-
tive in compromising glioma cell motility. Therefore,
alternative mechanism/s of the fenofibrate action should
be considered. One possibility is that fenofibrate anti-
cancer action could be associated with an aberrant cancer
cell energy metabolism. This idea originates from the pio-
neering work of Otto Warburg who demonstrated a dis-
tinctive dependence of tumor cells from glycolysis, even
when there is sufficient amount of oxygen available for
much more effective oxidative phosphorylation [38,55].
Only recently, it has been established that the inclination
of tumor cells for glycolysis is mainly driven by mito-
chondrial dysfunction [56,57]. A direct link between
mitochondrial aerobic respiration and carcinogenesis
have been provided by the demonstration that the loss of
p53 function, which is the most commonly mutated gene
in cancer [8], including Gliomas, results in the decrease
of synthesis of cytochrome C oxidase expression (SCO2)
[58]. SCO2 is crucial for the incorporation of mitochon-
drial DNA-encoded cytochrome C oxidase subunit
(MTCO2) into the cytochrome C oxidase complex. The
proper assembly of this complex is essential for the mito-
chondrial respiration. Therefore, SCO2 deficit in p53-
deficient cells heavily impairs oxidative phosphorylation
and may trigger the switch towards glycolysis [58].
In respect to the anti-cancer properties of fenofibrate,
activated PPARα, which is a transcriptional activator of
the fatty acid β-oxidation machinery [16], could switch
energy metabolism towards fatty acid degradation, and
decrease glucose uptake by repressing glucose trans-
porter GLUT4 [21,59]. Additionally, increased rate of oxi-
dation of fatty acids and ketone bodies forces the decline
in glucose utilization through the inhibition of glycolytic
enzymes [60,61]. This could be highly relevant to the
Glioma cells since their energy metabolism and the ability
to migrate is mitochondria independent and strongly
relies on glycolysis [62]. Therefore, one could speculate
that in glucose-dependent Glioma cells [62] with partial
mitochondrial dysfunction, fenofibrate could force an
aberrant mitochondrial oxidative phosphorylation lead-
ing to ROS accumulation, oxidative damage, and severe
deficit in ATP production.
In this respect our results indicate that indeed treat-
ment with fenofibrate was associated with ROS accumu-
lation (Fig. 3), which could be explained by the aberrant
function of the mitochondrial electron respiratory chain
at the level of NADH cytochrome C reductase [63], orDrukala et al. Molecular Cancer 2010, 9:159
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elevated xanthine oxidase expression [64], and cytosolic
ROS, by elevated peroxisomal β-oxidation or microsomal
ω-oxidation [64,65].
Fenofibrate is also known to be responsible for a strong
PPARα-dependent induction of mitochondrial uncou-
pling proteins, e.g. UCP2 [66] in various cell models,
therefore the decreased mitochondrial membrane poten-
tial observed in the fenofibrate treated LN-229 cells
might be attributed to this event as well. Since the Glioma
cell lines used in this study show much higher levels of
PPARα expression than control astrocytes, PPARα driven
UCP2 expression is not unlikely. UCP2 acting as a proto-
nophore facilitates passive proton flow through the mito-
chondrial inner membrane, which results in uncoupling
respiration from ATP production. Moreover, UCP2 has
been shown to act as a metabolic sensor, which promotes
the switch from glucose dependent metabolism towards
fatty acid and glutamine oxidation [67]. These two effects
may additionally contribute to the Glioma cell energy
depletion, which was manifested here by a severe inhibi-
tion of cell motility.
Since ROS scavenger, N-acetyl-cysteine (NAC), as well
as siRNA against human PPARα prevented ROS accumu-
lation, enhanced ATP production, and restored LN-229
cell motility, we have concluded that PPARα induced
metabolic switch towards mitochondria could be the
major contributing factor in the observed anti-cancer
action of fenofibrate. Therefore, in addition to the impair-
ment of the IGF-IR signaling responses, Glioma cells
treated with fenofibrate could be brought to the verge of
metabolic dysfunction by forcing mitochondrial oxidative
respiration in the tumor cells, which strongly depend on
glycolysis. This opens an opportunity for the use of
PPARα agonists, including fenofibrate, since it should be
selectively toxic for tumor cells and relatively harmless
for cells with normal mitochondrial function.
Conclusions
Our results show strong inhibition of Glioma cell motility
in vitro by fenofibrate, which involves ROS accumulation,
severe mitochondrial dysfunction and a deficit in ATP
production. The involvement of IGF-IR inhibition in this
process was less apparent despite of IGF-I supporting
role in glioma cell motility. Since fenofibrate has relatively
low systemic toxicity, its potential clinical use against
brain tumors including GBMs should be considered.
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